Biomarin Pharmaceutical (BMRN) EBIAT: 2009-2025
Historic EBIAT for Biomarin Pharmaceutical (BMRN) over the last 14 years, with Sep 2025 value amounting to -$30.7 million.
- Biomarin Pharmaceutical's EBIAT fell 128.98% to -$30.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $520.4 million, marking a year-over-year increase of 61.47%. This contributed to the annual value of $426.9 million for FY2024, which is 154.62% up from last year.
- Biomarin Pharmaceutical's EBIAT amounted to -$30.7 million in Q3 2025, which was down 112.78% from $240.5 million recorded in Q2 2025.
- Biomarin Pharmaceutical's 5-year EBIAT high stood at $240.5 million for Q2 2025, and its period low was -$57.9 million during Q4 2021.
- In the last 3 years, Biomarin Pharmaceutical's EBIAT had a median value of $88.7 million in 2024 and averaged $90.0 million.
- Its EBIAT has fluctuated over the past 5 years, first tumbled by 440.02% in 2021, then spiked by 8,282.73% in 2023.
- Over the past 5 years, Biomarin Pharmaceutical's EBIAT (Quarterly) stood at -$57.9 million in 2021, then spiked by 99.57% to -$249,000 in 2022, then surged by 8,282.73% to $20.4 million in 2023, then soared by 513.22% to $124.9 million in 2024, then tumbled by 128.98% to -$30.7 million in 2025.
- Its EBIAT stands at -$30.7 million for Q3 2025, versus $240.5 million for Q2 2025 and $185.7 million for Q1 2025.